

Sorrento Therapeutics, Inc.  
Form 8-K  
November 16, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 13, 2018**

**SORRENTO THERAPEUTICS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**

**001-36150**

**33-0344842**

(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation) File Number) Identification  
No.)

4955 Directors Place

San Diego, CA 92121

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (858) 203-4100

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ..

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

**Item 1.01. Entry into a Material Definitive Agreement.**

On November 13, 2018, Sorrento Therapeutics, Inc. (the “Company”) entered into a lease agreement (the “Lease Agreement”) for the premises in the building located at 4939 Directors Place, San Diego, California (the “Building”). The ten year and seven month lease with HCP Life Science Estates, Inc. is for approximately 61,207 rentable square feet located in the Building.

The initial term of the lease is expected to commence on April 1, 2019. The Company will be obligated to pay an average of approximately \$3.2 million in annual rent over the term of the lease.

Pursuant to the Lease Agreement, beginning not more than fifteen months prior to and not less than twelve months prior to the expiration of the term of the lease, the Company has the option to extend the lease for an additional five year term at then current market rates.

The foregoing summary of the Lease Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease Agreement, a copy of which the Company expects to file with the Company’s Annual Report on Form 10-K for the year ending December 31, 2018.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information regarding the Lease Agreement set forth under Item 1.01 of this Form 8-K is incorporated by reference in this Item 2.03.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 16, 2018 **SORRENTO THERAPEUTICS, INC.**

By: /s/ Henry Ji, Ph.D.

Name: Henry Ji, Ph.D.

Title: Chairman of the Board, President and  
Chief Executive Officer